Orphanet: Pesquisa simples
x

Pesquisar um ensaio clínico

* (*) campo(s) de preenchimento obrigatório

64 Resultado(s)

Ensaio em fase de recrutamento = Ensaio em fase de recrutamento; Ensaio a decorrer = Ensaio a decorrer; Financiado por um membro do IRDiRC =

Ensaio (s) clínico (s) nacional (is)

ALEMANHA

Baden-Württemberg
FREIBURG

ALEMANHA

Baden-Württemberg
HEIDELBERG

ALEMANHA

Berlin
BERLIN

Ensaio em fase de recrutamentoEnsaio a decorrerAMoRe2017: International multicenter, open-label, phase 2 study to treat molecular relapse of pediatric acute myeloid leukemia with Azacitidine -DE-
Otto-Heubner-Centrum für Kinder- und Jugendmedizin
Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie

ALEMANHA

Sachsen
DRESDEN

TUD-RELAZA-008: Treatment of the haematological relapse in patients with AML and MDS following allogenic Stem Cell Transplantation with 5-Azacitidine (Vidaza®) (Phase III) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

ALEMANHA

Sachsen
LEIPZIG

ALEMANHA

Sachsen
LEIPZIG

An open-label, multicenter study of monotherapy or in combination with azacitidine for patients with post-myeloproliferative disorders (Phase I/II) - DE
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie

BELGICA

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

Ensaio em fase de recrutamentoEnsaio a decorrerAMoRe2017: International multicenter, open-label, phase 2 study to treat molecular relapse of pediatric acute myeloid leukemia with Azacitidine - BE
Hôpital Universitaire des Enfants Reine Fabiola - HUDERF
Service d'hémato-oncologie, d'immunologie et de rhumatologie pédiatrique

FRANCA

ILE-DE-FRANCE
PARIS

Ensaio em fase de recrutamentoEnsaio a decorrerA phase II study of the efficacy and safety of lenalidomide combined to azacitidine in intermediate-2 or high risk MDS AND AML with del 5q (GFM-Aza-Rev-09)
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Groupe Francophone des Myélodysplasies (GFM)

FRANCA

ILE-DE-FRANCE
PARIS

Ensaio em fase de recrutamentoEnsaio a decorrerA phase I-II study of the efficacy and safety of idarubicin combined to azacitidine in int-2 or high risk myelodysplastic syndromes.
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Groupe Francophone des Myélodysplasies (GFM)

FRANCA

ILE-DE-FRANCE
PARIS

5-Azacitidine, Valproic Acid and ATRA in AML and High Risk MDS (Phase II) - Terminated -
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service : Centre des Maladies du Sang

Ensaio (s) clínico (s) multinacional (ais)